ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TA-MUC1/DXd Antibody-drug Conjugate DS-3939a

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis, led by Daiichi Sankyo.

Furthest: phase 2, since May 10, 20232 company-led studies, 2 open or runningNext primary completion: Aug 11, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyo22 open or runningphase 2since May 10, 2023May 10, 2023Aug 11, 2028phase 2 · NCT05875168

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2023First study: phase 2 study in Neoplasm MetastasisFirst studyNCT05875168 · 590 planned · United States, Belgium, Canada and more
  2. Jul 28, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07739966 · 400 planned · United States, Argentina, Austria and more
  3. Oct 15, 2026Primary completion moved from 2026-10-20 to 2028-08-11Date moved laterphase 2 · +22 months · NCT05875168

Ahead

  1. Aug 11, 2028Primary completion: phase 2 study in Neoplasm MetastasisNCT05875168
  2. Jul 31, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07739966

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07739966Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more2RecruitingJul 31, 2030400
NCT05875168Neoplasm Metastasis · United States, Belgium, Canada and more2RecruitingAug 11, 2028590

How it is read

Names in the registry

  • “DS-3939a”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.